Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond.
Walsh MC, Choi Y. · 2014
Read Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. by Walsh MC, Choi Y. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4202272.txt.
Introduction
Matthew C. Walsh and Yongwon Choi reviewed a three-part signalling system in Frontiers in Immunology in 2014. The system joins RANKL, a signal protein, its receptor RANK, and OPG, a decoy receptor that soaks the signal up. It was first mapped in bone, where it balances bone building and bone breakdown.
The same trio turns out to steer much more. It shapes the development of lymph nodes and other organs, trains immune tolerance, and plays a part in cancer spread to bone. Its discovery helped found the field of osteoimmunology, the study of how bone and immunity talk to each other. A drug blocking RANKL already treats osteoporosis. The review gathers the system's basic biology and points to new areas, from fever control to breast development, where it also acts.
Catalog record
| CREATOR | Walsh MC, Choi Y. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond By Matthew C Walsh, Yongwon Choi Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2014.00511 ABSTRACT Abstract Discovery and characterization of the cytokine receptor-cytokine-decoy receptor triad formed by receptor activator of nuclear factor kappa-B ligand (RANKL)–receptor activator of NF-κB (RANK)–osteoprotegerin (OPG) have led not only to immense advances in understanding the biology of bone homeostasis, but have also crystalized appreciation of the critical regulatory relationship that exists between bone and immunity, resulting in the emergence of the burgeoning field of osteoimmunology. RANKL–RANK–OPG are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies, and share signaling characteristics common to many members of each. Developmentally regulated and cell-type specific expression patterns of each of these factors have revealed key regulatory functions for RANKL–RANK–OPG in bone homeostasis, organogenesis, immune tolerance, and cancer. Successful efforts at designing and developing therapeutic agents targeting RANKL–RANK–OPG have been undertaken for osteoporosis, and additional efforts are underway for other conditions. In this review, we will summarize the basic biology of the RANKL–RANK–OPG system, relate its cell-type specific functions to system-wide mechanisms of development and homeostasis, and highlight emerging areas of interest for this cytokine group. Keywords: osteoimmunology, TRAF6, TRANCE, RANKL, TNFSF11, TNFRSF11, mTECs, rheumatoid arthritis INTRODUCTION Functional diversity typifies the cytokines and receptors of the tumor necrosis factor (TNF) and tumor necrosis factor receptor (TNFR) superfamilies. TNF superfamily (TNFSF) members are broadly expressed in a variety of tissues and organ systems, and are commonly associated with expression on cells of the immune system. In recent years, studies of TNF/TNFR superfamily members have been responsible for elucidating previously unrecognized linkages between the immune system and other biological systems, as well as previously unrealized networks controlling various disease conditions (1, 2). An important example is the system consisting of the cytokine receptor activator of nuclear factor kappa-B ligand [RANKL; additionally identified as TNF-related activation-induced cytokine (TRANCE), osteoclast differentiation factor (ODF), and TNFSF11], its signaling receptor receptor activator of NF-κB (RANK), and the soluble decoy receptor osteoprotegerin (OPG). The RANKL–RANK–OPG system was originally discovered through parallel efforts in the late 1990s that identified it as important to immunity, primarily via actions on dendritic cells (DCs) (3, 4), and as important to bone homeostasis through regulation of osteoclasts (OCs) (5, 6). Work employing various genetically deficient mouse models has shown the critical role of the RANKL–RANK–OPG system plays in bone and immunity – significantly contributing to the emergence of the field of osteoimmunology – as well as organogenesis, and disease conditions including cancer and rheumatoid arthritis (RA). In this review, we will provide a summary of current understanding of the biological functions of the RANKL–RANK–OPG system in development, homeostasis, immunity, and disease, as well as ongoing efforts to target RANKL–RANK–OPG to prevent or fight diseases like osteoporosis and cancer. RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND Receptor activator of nuclear factor kappa-B ligand (3), which was independently discovered by four groups, is alternatively named TRANCE (4), ODF (6), osteoprotegerin ligand (OPGL) (5), and designated TNFSF11. The gene encoding the RANKL protein, Tnfsf11, is located on human chromosome 13q14, and a conserved syntenic region on mouse chromosome 14 (4). RANKL protein is a type II membrane protein bearing close homology to TNFSF members TRAIL, FasL, and TNF-a (4). Full-length murine RANKL is 316 amino acids, shares 83% sequence homology with human RANKL (4), and consists of a C-terminal extra-cellular receptor-interacting domain and a transmembrane domain, but is found in both membrane-bound and soluble forms (7). Cleavage of soluble RANKL from the membrane-embedded portion is mediated by the metalloprotease–disintegrin TNF-a convertase (TACE) (8, 9). Further, three distinct isoforms of RANKL message have been identified, the shortest of which – lacking the intracellular and transmembrane domains – may have inhibitory function (10). These data comport with observations that soluble RANKL is less efficient at mediating osteoclastogenesis (11). RANKL expression has been detected in various tissues including T lymphocytes (4), osteoblasts (OBs), osteocytes and bone stroma, and lung (5, 6, 12, 13). Throughout development RANKL mRNA can be detected in the brain, heart, kidneys, skeletal muscle, and skin of mouse embryos, and has been specifically identified in E15 chondrocytes (5, 12). Expression of RANKL is highly inducible, and is regulated by various osteoactive factors including glucocorticoids (14), Vitamin D3 [1,25(OH)2D3] (6, 15), IL-1 (16), TNF-a (16), TGF-b (17), Wnt ligands (18), and LPS (19). Binding studies show that RANKL can bind to both the functional receptor RANK and the decoy receptor OPG (3, 5). RECEPTOR ACTIVATOR OF NF-ΚB Receptor activator of NF-κB [(3); alternatively identified as TNF-related activation-induced cytokine receptor (TRANCE-R) (20) or osteoclast differentiation and activation receptor (ODAR) (21)] is the signaling receptor for RANKL. RANK has been designated TNFRSF11A, and is a type I 616 amino acid homo-trimerizing transmembrane protein containing four extra-cellular cysteine-rich pseudorepeats. Trimerization is promoted by interaction with RANKL (22). The human gene that encodes RANK, Tnfrsf11a, is located on chromosome 18q22.1 (3), and RANK message is detected in thymus, liver, colon, mammary glands, prostate, pancreas, bone marrow, heart, lung, brain, skeletal muscle, kidney, liver, and skin (3, 7, 23). RANK is strongly induced, especially on OC precursor cells, by M-CSF (24). Typical of TNFRSF members, RANK lacks intrinsic kinase activity and must rely on recruiting factors capable of activating downstream signaling pathways (summarized in Figure 1). As such, RANK intracellular signal transduction is mediated first through direct interaction with tumor necrosis factor receptor-associated factors (TRAFs), which are recruited upon receptor activation (25, 26). RANK interacts with TRAFs 1, 2, 3, 5 in a membrane-distal region of the 383 amino acid cytoplasmic tail, and with TRAF6 at a distinct membrane-proximal Pro-X-Glu-X-X-(aromatic/acid residue) binding motif (25–27). TRAF6 is critical activating mitogen-activated protein kinases (MAPKs) p38 and JNK, as well as the canonical NF-κB pathway in response to RANK signaling (8, 28, 29). TRAF6 utilizes the adapter TAB2 to interact with the MAPK kinase TAK1 to mediate RANK signaling (30). While RANK binds similar TRAFs as the related receptor CD40, it has been shown that stronger activation of TRAF6 may account for unique RANK function (31). Other interacting factors that may modulate RANK signaling include Grb2-associated binding protein 2 (Gab2) (32), epidermal growth factor receptor (EGFR) (33), four-and-a-half LIM domain 2 (FHL2) (34), Lyn (35), CYLD de-ubiquitinase (36), and TRAF family member-associated NF-κB activator (TANK) (37). It has been shown that RANK signaling can regulate calcium oscillation through downstream activation of regulator of G-protein signaling 10 (RGS10) (38), and that RANK-mediated calcium flux is itself regulated by transmembrane protein 64 (TMEM64) interaction with sarcoplasmic endoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) (39). RANK also activates Src family kinase signaling in a manner that leads to Akt/PKB activation through interactions between TRAF6 and Cbl scaffolding proteins (40, 41). TRAF6-dependent RANK signaling has been shown to be negatively regulated via cross-talk with the IFN-g signaling pathway, employing a mechanism leading to TRAF6 ubiquitination and degradation (42). More recently, it has been shown that TRAF3 plays a key role in negatively regulating RANK-mediated activation of the non-canonical NF-κB pathway (43). One of the signaling properties of RANK that may distinguish it functionally from some other TNFR superfamily members is its capacity to activate both the canonical and